Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a ...

The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes ...

The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat ...

Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers ...

The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts ...

At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors ...

A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped ...

The company is now hoping for an affirmative answer on its application after an unusually turbulent year dealing with U.S.

Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but ...

With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two ...

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management ...

Deals with Chinese drugmakers are continuing at a steady pace, while two mid-cap biotechs' stock prices took a tumble this ...